Vascular-targeted photodynamic therapy in the treatment of neovascular age-related macular degeneration: Clinical perspectives

Photodiagnosis and Photodynamic Therapy

Volumn 12, Issue 2, 2015, Pages 161-175

  Kawczyk Krupka, A ^a,b,c   Bugaj, A M ^a,b,c,e   Potempa, M ^b,c   Wasilewska, K ^d   Latos, W ^a,b,c   Sieron A ^a,b,c  

^a Center for Laser Diagnostics and Therapy   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c The Department of Medicine and Division of Medicine and Dentistry   (Poland)

^d NEWNHAM COLLEGE   (United Kingdom)

^e Beauty Care and Education   (Poland)

Author keywords

Age related macular degeneration; Clinical trials; Vascular targeted photodynamic therapy; Verteporfin

Indexed keywords

VERTEPORFIN; ANGIOGENESIS INHIBITOR; CORTICOSTEROID; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; PORPHYRIN; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; IRRADIATION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PHOTODYNAMIC THERAPY; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW; VISUAL ACUITY; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; COMBINATION DRUG THERAPY; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PROCEDURES;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84930473789     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2015.03.007     Document Type: Review

References (122)

1. Lim L.S., Mitchell P., Seddon J.M., Holz F.G., Wong T.Y. Ophthalmology 1. Age-related macular degeneration. Lancet 2012, 379:1728-1738.
2. Nowak-Śliwinska P., Weiss A., Sickenberg M., Griffioen A.W., van den Bergh H. The role of photodynamic therapy in non-malignant and malignant eye disorders. J Anal Bioanal Tech 2013, S1.007 (15 pages). 10.4172/2155-9872.S1-007.
3. Maguire M.G. Natural history. Age-related macular degeneration 1999, 17-30. Mosby, St. Louis. J.W. Burger, S.L. Fine, M.G. Maguire (Eds.).
4. Augustin A.J., Scholl S., Kirchhof J. Treatment of neovascular age-related macular degeneration: current therapies. Clin Ophthalmol 2009, 3:175-182.
5. Miller J.W. Treatment of age-related macular degeneration: beyond VEGF. Jpn J Ophthalmol 2010, 54:523-528.
6. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011, 61:250-281.
7. Bugaj A.M. Targeted photodynamic therapy-a promising strategy of tumor treatment. Photochem Photobiol Sci 2011, 10:1097-1109.
8. Hu Z., Oleinick N., Hamblin M.R. Photodynamic therapy as an emerging treatment modality for cancer and non-cancer diseases. J Anal Bioanal Tech 2014, S1:e001. (3 pages). 10.4172/2155-9872.S1-e001.
9. Olivo M., Bhuvaneswari R., Lucky S.S., Dendukuri N., Soo-Ping Thong P. Targeted therapy of cancer using photodynamic therapy in combination with multi-faceted anti-tumor modalities. Pharmaceuticals 2010, 3:1507-1529.
10. Schmidt-Erfurth U., Hasan T., Gragoudas E., Michaud N., Flotte T.J., Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994, 101:1953-1961.
11. Miller J.W., Walsh A.W., Kramer M., Hasan T., Michaud N., Flotte T.J., et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 1995, 113:810-818.
12. Jurklies B., Bornfeld N. The role of photodynamic therapy in retinal vascular disease. Retinal vascular disease. Section II. General concepts in the diagnosis and treatment of retinal vascular disease 2007, 239-255. Springer-Verlag, Berlin-Heidelberg. A.M. Joussen, T.W. Gardner, B. Kirchhof, S.J. Ryan (Eds.).
13. Lim J.I. Photodynamic therapy for choroidal neovascular disease: photosensitizers and clinical trials. Ophthalmol Clin North Am 2002, 15:473-478.
14. Huang Z. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 2005, 4:283-293.
15. Richter A.M., Waterfield E., Jain A.K., Allison B., Sternberg E.D., Dolphin D., et al. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumor model. Br J Cancer 1991, 63:87-93.
16. Reinke M.H., Canakis C., Husain D., Michaud N., Flotte T.J., Gragoudas E.S., et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology 1999, 106:1915-1923.
17. Verteporfin. In: PharmacyCodes Medical Directory. Digital Ocean Inc. Last updated 19.12.2014. 〈https://pharmacycode.com/Verteporfin.html〉 (accessed 8.04.2015).
18. Visudyne® (Drug Information) vid240913i.doc 2013, Novartis, North Ryde.
19. Allison B.A., Waterfield E., Richter A.M., Levy J.G. The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative. Photochem Photobiol 1991, 54:709-715.
20. Schmidt-Erfurth U., Bauman W., Gragoudas E. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 1994, 101:89-99.
21. Schmidt-Erfurth U., Diddens H., Birngruber R., Hasan T. Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Ophthalmol 1997, 75:54-61.
22. Bonnett R. Chemical aspects of photodynamic therapy 2000, p. 286. Gordon and Breach Publishing House, Amsterdam-Singapore.
23. Richter A.M., Cerruti-Sola S., Sternberg E.D., Dolphin D., Levy J.G. Biodistribution of tritiated benzoporphyrin derivative (3H-BPDMA), a new potent photosensitizer, in normal and tumor-bearing mice. J Photochem Photobiol B 1990, 5:231-244.
24. Richter A.M., Kelly B., Chow J., Liu D.J., Towers G.H.N., Dolphin D., et al. Preliminary studies on a more effective phototoxic agent than hematoporphyrin. J Natl Cancer Inst 1987, 79:1327-1332.
25. ® registry databases. Annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2009, Registry Investigator Groups, (Poster A593).
26. Wolf S., Balciuniene V.J., Laganovska G., Menchini U., Ohno-Matsui K., Sharma T., et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014, 121. 682.e2-692.e2.
27. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 1999, 117:1329-1345. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.
28. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001, 119:198-207. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.
29. Verteporfin of subfoveal choroidal neovascularization in pathologic myopia. 2 year results of a randomized clinical trial-VIP report No. 3. Ophthalmology 2003, 110:667-673. Verteporfin in Photodynamic Therapy Study Group.
30. Verteporfin Roundtable Participants Guidelines for using Verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005, 25:119-134.
31. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with Verteporfin. 1-year results of a randomized clinical trial-VIP report No. 1. Ophthalmology 2001, 108:841-852. Verteporfin in Photodynamic Therapy Study Group (VIP).
32. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001, 131:541-560. Verteporfin in Photodynamic Therapy Study Group (VIP).
33. Visudyne in Minimally Classic Choroidal Neovascularization Study Group (VIM) Verteporfin therapy of subfoveally minimally classic choroidal neovascularization in agerelated macular degeneration. Arch Ophthalmol 2005, 123:448-457.
34. Azab M., Boyer D.S., Bressler N.M., Bressler S.B., Cihelkova I., Hao Y., et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005, 123:448-457.
35. Michels S., Hansmann F., Geitzenauer W., Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006, 47:371-376.
36. Gallemore R.P., Boyer D.S. PDT or Anti-VEGF for AMD Treatment. What the clinical trials tell us about how to approach AMD treatment today. Rev Ophthalmol 2006, 2. 〈http://www.revophth.com/content/d/retinal_insider/i/1308/c/25171/〉 (accessed 13.09.2014).
37. Kaiser P.K. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 2006, 244:1132-1142. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group.
38. European Medicines Agency (EMA) Visudyne. Scientific Discussion. Procedure no: EMEA/H/C/000305/II/0053 2007, 〈http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_Variation/human/000305/WC500052408.pdf〉 (accessed 05.03.2015).
39. Axer-Siegel R., Ehrlich R., Rosenblatt I., Kramer M., Priel E., Yassur Y., et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol 2004, 122:453-459.
40. Frennesson C.I., Nilsson S.E. Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration. Acta Ophthalmol Scand 2004, 82:645-650.
41. Yang N., Fan C.M., Ho C.K. Review of first year result of photodynamic therapy on age-related macular degeneration in a Chinese population. Eye 2006, 20:523-526.
42. Manku K.K., Rotchford A., Whitaker J., Amoaku W.M. Factors influencing poor visual outcome in patients treated with photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration. Clin Exp. Ophthalmol 2007, 35:330-334.
43. Potter M.J., Szabo S.M., Li W.W. Comparison of visual acuity outcomes in predominantly classic vs occult lesions in age-related macular degeneration treated with photodynamic therapy. Eye 2008, 22:194-199.
44. QLT Inc. A randomized, placebo-controlled, double-masked, multicenter, phase III study of the effect of Visudyne therapy in occult with no classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD): Visudyne in occult (VIO). NCT00121407 2005, last updated: July 19, 2005. 〈https://clinicaltrials.gov/ct2/show/NCT00121407〉 (accessed 5.03.2015).
45. European Medicines Agency (EMA) Visudyne. Procedural steps taken and scientific information after the authorisation 2014, 〈http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000305/WC50005〉 (accessed 5.03.2015).
46. Cruess A.F., Zlateva G., Pleil A.M., Wirostko B. Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol 2009, 87:118-132.
47. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) & Verteporfin in Photodynamic Therapy (VIP) Study Groups Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration. TAP and VIP Report 1. Am J Ophthalmol 2003, 136:407-418.
48. Rosenfeld P.J., Boyer D.S., Bressler N.M., Fish G., Grizzard W.S., Hao Y., et al. Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO study. Am J Ophthalmol 2007, 144:970-972.
49. Blinder K.J., Bradley S., Bressler N.M., et al. Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group: Verteporfin in Photodynamic Therapy study group Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003, 136:407-418.
50. Sickenberg M., Schmidt-Erfurth U., Miller J.W., Pournaras C.J., Zografos L., Piguet B., et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 2000, 118:327-336.
51. Schlötzer-Schrehardt U., Viestenz A., Naumann G.O.H., Laqua H., Michels S., Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002, 240:748-757.
52. Schmidt-Erfurth U., Laqua H., Schlötzer-Schrehardt U., Viestenz A., Naumann G.O.H. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002, 120:835-844.
53. Postelmans L., Pasteels B., Coquelet P., El Ouardighi H., Verougstraete C., Schmidt-Erfurth U. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 2004, 138:803-808.
54. Jurklies B., Anastassiou G., Ortmans S., Schüler A., Schilling H., Schmidt-Erfurth U., et al. Photodynamic therapy using Verteporfin in circumscribed choroidal hemangioma. Br J Ophthalmol 2003, 87:84-89.
55. Schmidt-Erfurth U., Michels S., Kusserow C., Jurklies B., Augustin A. Photodynamic therapy for symptomatic choroidal hemangioma: visual and anatomic results. Ophthalmology 2002, 109:2284-2294.
56. Wachtlin J., Behme T., Heimann H., Kellner U., Foerster M.H. Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2003, 241:518-521.
57. Ghazi N.G., Jabbour N.M., De La Cruz Z.C., Green W.R. Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina 2001, 21:478-486.
58. Gelisken F., Lafaut B.A., Inhoffen W., Voelker M., Grisanti S., Bartz-Schmidt K.U. Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. Br J Ophthalmol 2004, 88:207-211.
59. Moshfeghi D.M., Kaiser P.K., Grossniklaus H.E., Sternberg P., Sears J.E., et al. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 2003, 135:343-350.
60. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
61. Kliffen M., Sharma H.S., Mooy C.M., Kerkvliet S., de Jong P.T. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997, 81:154-162.
62. Probodh I., Cramb D.T. Two-photon excitation photodynamic therapy: working toward a new treatment for wet age-related macular degeneration. Age related macular degeneration-the recent advances in basic research and clinical care 2012, 212-226. InTech, Rijeka-Shanghai, (Chap. 11). G.-S. Ying (Ed.).
63. Gragoudas E.S., Adamis A.P., Cunningham E.T., Feinsod M., Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004, 351:2805-2816.
64. Heier J.S., Brown D.M., Chong V., Korobelnik J.F., Kaiser P.K., Nguyen Q.D., et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012, 119:2537-2548.
65. Papadopoulos N., Martin J., Ruan Q., Rafique A., Rosconi M.P., Shi E., et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012, 15:171-185.
66. GlaxoSmithKline A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib drops, administered for 28 days to adult subjects with neovascular age-related macular degeneration. NCT00612456 2013, Last verified: February 2013 〈https://clinicaltrials.gov/ct2/show/NCT00612456〉 (accessed: 5.03.2015).
67. Novartis A randomized, double-masked, multicenter, Phase I/II study of the safety of PTK787 administered to patients with predominantly classic, minimally classic or occult with no classic subfoveal choroidal neovascularization secondary to age-related macular degeneration. NCT00138632 2008, Last verified: November 2008. 〈https://clinicaltrials.gov/ct2/show/NCT00138632〉 (accessed 5.03.2015).
68. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1432-1444.
69. Brown D.M., Michels M., Kaiser P.K., Heier J.S., Sy J.P., Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009, 116. ANCHOR Study Group, 57.e5-65.e5.
70. Augustin A.J., Scholl S., Kirchhof J. Treatment of neovascular age-related macular degeneration: Current therapies. Clin Ophthalmol 2009, 3:175-182.
71. Schmidt-Erfurth U., Michels S., Michels R., Aue A. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol 2005, 15:482-485.
72. Slakter J.S., Bochow T., D'Amico D.J., Marks B., Jerdan J., Sullivan E.K. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006, 113:3-13.
73. Alcon Research Phase 3 study to evaluate Anecortave Acetate vs. Visudyne for the treatment of the wet form of AMD. NCT00041483 2014, Last updated 30.06.2014. 〈https://clinicaltrials.gov/ct2/show/study/NCT00041483〉 (accessed 03.03.2015).
74. Meads C., Salas C., Roberts T., Moore D., Fry-Smith A., Hyde C. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003, 7:1-98.
75. Sharma S., Brown G.C., Brown M.M., Hollands H., Shah G.K. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001, 108:2051-2059.
76. Hopley C., Salkeld G., Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol 2004, 88:982-987.
77. Smith D.H., Fenn P., Drummond M. Cost-effectiveness of photodynamic therapy with verteporfin for age-related macular degeneration: the UK case. Br J Ophthalmol 2004, 88:1107-1112.
78. Greiner R.A. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol 2001, 16:218-222.
79. Brown G.C., Brown M.M., Campanella J., Beauchamp G.R. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration-a value-based reappraisal with 5-year data. Am J Ophthalmol 2005, 140:679-687.
80. Mitchell P., Annemans L., White R., Gallagher M., Thomas S. Cost effectiveness of treatments for wet age-related macular degeneration. Pharmacoeconomics 2011, 29:107-131.
81. Spaide R.F., Sorenson J., Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 2005, 25:685-690.
82. Michels S., Hansmann F., Geitzenauer W., et al. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006, 47:371-376.
83. Spaide R.F., Sorenson J., Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003, 110:1517-1525.
84. Spaide R.F., Sorenson J., Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005, 112:301-304.
85. Chan W-M., Lai T.Y.Y., Wong A.L., Tong J-P., Liu D.T.L., Lam D.S.C. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 2006, 90:337-341.
86. Augustin A.J., Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006, 113:14-22.
87. Antoszyk A.N., Tuomi L., Chung C.Y., Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008, 145:862-874. FOCUS Study Group.
88. Schmidt-Erfurth U., Wolf S. Same-day administration of verteporfin and ranibizumab 0.5mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 2008, 92:1628-1635. PROTECT Study Group.
89. QLT QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne® combination therapy June, 2009, 〈http://www.qltinc.com/newsCenter/2009/090615.htm〉 (accessed 5.03.2015).
90. Larsen M., Schmidt-Erfurth U., Lanzetta P., Wolf S., Simader C., et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012, 119:992-1000.
91. Kaiser P.K., Boyer D.S., Cruess A.F., Slakter J.S., Pilz S., Weisberger A. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012, 119:1001-1010. DENALI Study Group.
92. Costa R.A., Jorge R., Calucci D., Melo L.A.S., Cardillo J.A., Scott I.U. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007, 245:1273-1280.
93. Lazić R., Gabrić N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007, 114:1179-1185.
94. Potter M.J., Claudio C.C., Szabo S.M. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol 2010, 94:174-179.
95. Costagliola C., Romano M.R., Rinaldi M., dell'Omo R., Chiosi F., Menzione M., et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol 2010, 94:180-184.
96. Liggett P.E., Colina J., Chaudhry N.A., Tom D., Haffner G. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 2006, 142:1072-1074.
97. Augustin A.J., Puls S., Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007, 27:133-140.
98. Augustin A.J., Rizzo S., Kirchhof J., Grus F. Intravitreal VEGF values and inflammatory parameters-rationale and clinical results of an individualized combination treatment of wet AMD. Paper presented at Retina Congress 2009.
99. Bakri S.J., Couch S.M., McCannel C.A., et al. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 2009, 29:573-578.
100. Hudson H. RADICAL: results of a randomized clinical trial of reduced fluence vPDT-anti-VEGF-dexamethasone in AMD. The Retina Congress 2009, For the RADICAL Study Group, (Poster 728).
101. Nelson M.H. ICG-directed PDT with Visudyne in combination with intravitreal Lucentis/triamcinolone acetonide as rescue therapy for non-VEGF driven processes in exudative age-related macular degeneration. Annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2009, (E-abstract: A591 (poster)).
102. Veritti D., Lanzetta P., Cascavilla M.L., Drigo D., Bandello F. Triple therapy for choroidal neovascularization due to age-related macular degeneration. Ranibizumab, modified juxtascleral triamcinolone acetonide, and verteporfin PDT. Annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2009, (E-abstract: A598 (poster)).
103. Yip P.P., Woo C.F., Tang H.H., Ho C.K. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol 2009, 93:754-758.
104. Sheidow T., Hooper P.J., Kertes C.E., Schwartz D.A.L., Maberley P., Ma B.J., et al. Combination therapy in neovascular age-related macular degeneration (AMD): a three-armed, randomized, prospective clinical trial of low fluence photodynamic therapy (RPDT) with adjunctive avastin and triamcinolone acetonide (Kenalog) (triple therapy) versus RPDT with adjunctive avastin (double therapy) versus monotherapy with Avastin. E-abstract: annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2009, (E-abstract: 1922-A612 (paper)).
105. Hughes M.S., Sang D.N. Triple therapy: reduced duration PT plus dexamethasone and ranibizumab vs. monthly ranibizumab for the treatment of exudative AMD: one year results. Paper presented at Retina Congress 2009.
106. Busquets M.A., Boscarino M.A., Guardiola A.A., Jewart B.H. Triple therapy for monthly ranibizumab monotherapy failures. Paper presented at Retina Congress 2009.
107. Maloney S.C., Fernandes B.F., Castiglione E., Antecka E., Martins C., Marshall J.C., et al. Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina 2009, 29:176-180.
108. Sin M., Chrapek O., Karhanova M., Pracharova Z., Langova K., Rehak J. Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014, 158:138-143.
109. Nakata I., Tsujikawa A., Yamashiro K., Otani A., Ooto S., Akagi-Kurashige Y., et al. Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 2013, 251:1073-1080.
110. Nowak-Śliwińska P., van den Bergh H., Sickenberg M., Koh A.H.C. Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res 2013, 37:182-199.
111. Smiddy W.E. Economic implications of current age-related macular degeneration treatments. Ophthalmology 2009, 116:481-487.
112. Schmidt-Erfurth U., Chong V., Loewenstein A., Larsen M., Souied E., Schlingemann R., et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014, 98:1144-1167.
113. Ziemssen F., Heimann H. Evaluation of verteporfin pharmacokinetics-redefining the need of photosensitizers in ophthalmology. Expert Opin Drug Metab Toxicol 2012, 8:1023-1041.
114. Deng H., Li T., Xie J., Huang N., Gu Y., Zhao J. Synthesis and bio-evaluation of novel hypocrellin derivatives: potential photosensitizers for photodynamic therapy of age-related macular degeneration. Dyes Pigm 2013, 99:930-939.
115. Collins H.A., Khurana M., Moriyama E.H., et al. Blood-vessel closure using photosensitizers engineered for two-photon excitation. Nat Photon 2008, 2:420-424.
116. Brown S. Two photons are better than one. Nat Photon 2008, 2:394-395.
117. Drobizhev M., Stepanenko Y., Dzenis Y., Karotki A., Rebane A., Taylor P.N., et al. Extremely strong near-IR two-photon absorption in conjugated porphyrin dimers: quantitative description with three-essential-states model. J Phys Chem B 2005, 109:7223-7236.
118. Kobuke Y., Ogawa K. Recent advances in two-photon photodynamic therapy. Anticancer Agents Med Chem 2008, 8:269-279.
119. Sharma R., Geng Y., Yin L., Merigan W.H., Williams D.R., Hunter J.J. In vivo two-photon imaging of mouse retina. Invest Ophthalmol Vis Sci 2012, 53. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), (E-abstract: 5600 (paper)).
120. Abouammoh M., Sharma S. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration. Curr Opin Ophthalmol 2011, 22:152-158.
121. Chiang A., Regillo C.D. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2011, 22:199-204.
122. Ozawa Y., Suzuki M., Niikura S., Kamoshita M., Nagai N., Tsubota K. Neuroprotective role of VEGF induced in response to photodynamic therapy. Adv Neuroimmun Biol 2013, 4:161-165.